Analytical Data
-
Gene name
BMPR1A/ALK-3
- Application
-
Alternative Names
Bone morphogenetic protein receptor type-1A; ALK-3; SKR5; CD292; ACVRLK3; BMPR-IA
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His;C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P36894
-
Expression Region
Q24-R152
-
Protein Length
Extracellular Domain
-
Molecular Weight
60.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BMPR1A, also known as ALK-3, is a member of the bone morphogenetic protein (BMP) receptor family, which plays a crucial role in various biological processes, including embryonic development, bone formation, and the regulation of cellular differentiation. The receptor is primarily involved in the BMP signaling pathway, which is essential for maintaining homeostasis and facilitating tissue regeneration. Dysregulation of this pathway has been implicated in several pathological conditions, including osteogenesis imperfecta, pulmonary arterial hypertension, and certain cancers. Given its significant role in both normal physiological processes and disease states, the study of recombinant BMPR1A/ALK-3 proteins has gained attention in biomedical research. This research not only facilitates a deeper understanding of BMP signaling mechanisms but also highlights the potential therapeutic avenues for targeting BMPR1A to treat related disorders. Recombinant BMPR1A proteins can be employed in various applications, including cell signaling studies, development of bioactive implants, and drug discovery efforts aimed at modulating BMP pathways. Overall, the exploration of BMPR1A/ALK-3 through recombinant protein technology is crucial for advancing both fundamental research and the development of novel therapies.
